Formulation, Inflammation, and RNA Sensing Impact the Immunogenicity of Self-amplifying RNA Vaccines

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2023 Jan 2

PMID 36589712

Authors

John S Tregoning

David C Stirling

Ziyin Wang

Katie E Flight

Jonathan C Brown

Anna K Blakney

Paul F McKay

Robert F Cunliffe

Valarmathy Murugaiah

Christopher B Fox

Mitchell Beattie

Ying K Tam

Cecilia Johansson

Robin J Shattock

Affiliations

Soon will be listed here.

Abstract

To be effective, RNA vaccines require both translation and the induction of an immune response to recruit cells to the site of immunization. These factors can pull in opposite directions with the inflammation reducing expression of the vaccine antigen. We investigated how formulation affects the acute systemic cytokine response to a self-amplifying RNA (saRNA) vaccine. We compared a cationic polymer (pABOL), a lipid emulsion (nanostructured lipid carrier, NLC), and three lipid nanoparticles (LNP). After immunization, we measured serum cytokines and compared the response to induced antibodies against influenza virus. Formulations that induced a greater cytokine response induced a greater antibody response, with a significant correlation between IP-10, MCP-1, KC, and antigen-specific antibody titers. We then investigated how innate immune sensing and signaling impacted the adaptive immune response to vaccination with LNP-formulated saRNA. Mice that lacked MAVS and are unable to signal through RIG-I-like receptors had an altered cytokine response to saRNA vaccination and had significantly greater antibody responses than wild-type mice. This indicates that the inflammation induced by formulated saRNA vaccines is not solely deleterious in the induction of antibody responses and that targeting specific aspects of RNA vaccine sensing might improve the quality of the response.

Citing Articles

Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen.

Casmil I, Bathula N, Huang C, Wayne C, Cairns E, Friesen J Mol Ther. 2025; 33(2):514-528.

PMID: 39741413 PMC: 11852984. DOI: 10.1016/j.ymthe.2024.12.055.

A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates.

Vijayan A, Vogels R, Groppo R, Jin Y, Khan S, Van Kampen M Nat Commun. 2024; 15(1):9884.

PMID: 39543172 PMC: 11564874. DOI: 10.1038/s41467-024-54289-9.

A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach.

Feng S, Rcheulishvili N, Jiang X, Zhu P, Pan X, Wei M Int J Biol Sci. 2024; 20(6):2111-2129.

PMID: 38617529 PMC: 11008270. DOI: 10.7150/ijbs.87741.

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19.

Silva-Pilipich N, Beloki U, Salaberry L, Smerdou C Vaccines (Basel). 2024; 12(3).

PMID: 38543952 PMC: 10974399. DOI: 10.3390/vaccines12030318.

mRNA vaccine designs for optimal adjuvanticity and delivery.

Mochida Y, Uchida S RNA Biol. 2024; 21(1):1-27.

PMID: 38528828 PMC: 10968337. DOI: 10.1080/15476286.2024.2333123.

References

Arimori Y, Nakamura R, Yamada H, Shibata K, Maeda N, Kase T . Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res. 2013; 99(3):230-7. DOI: 10.1016/j.antiviral.2013.05.007. View

Groves H, McDonald J, Langat P, Kinnear E, Kellam P, McCauley J . Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy. Front Immunol. 2018; 9:126. PMC: 5797846. DOI: 10.3389/fimmu.2018.00126. View

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View

van Boxel-Dezaire A, Rani M, Stark G . Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006; 25(3):361-72. DOI: 10.1016/j.immuni.2006.08.014. View

Shirai S, Kawai A, Shibuya M, Munakata L, Omata D, Suzuki R . Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses. Vaccines (Basel). 2020; 8(3). PMC: 7565178. DOI: 10.3390/vaccines8030433. View

McKay P, Cizmeci D, Aldon Y, Maertzdorf J, Weiner J, Kaufmann S . Identification of potential biomarkers of vaccine inflammation in mice. Elife. 2019; 8. PMC: 6555592. DOI: 10.7554/eLife.46149. View

Lazear H, Lancaster A, Wilkins C, Suthar M, Huang A, Vick S . IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog. 2013; 9(1):e1003118. PMC: 3536698. DOI: 10.1371/journal.ppat.1003118. View

Tregoning J, Flight K, Higham S, Wang Z, Pierce B . Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-636. PMC: 8351583. DOI: 10.1038/s41577-021-00592-1. View

Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyarto B . The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021; 24(12):103479. PMC: 8604799. DOI: 10.1016/j.isci.2021.103479. View

10.

Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D . Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021; 36(6):109504. PMC: 8299183. DOI: 10.1016/j.celrep.2021.109504. View

11.

Davies N, Hovdal D, Edmunds N, Nordberg P, Dahlen A, Dabkowska A . Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein. Mol Ther Nucleic Acids. 2021; 24:369-384. PMC: 8039535. DOI: 10.1016/j.omtn.2021.03.008. View

12.

Minnaert A, Vanluchene H, Verbeke R, Lentacker I, De Smedt S, Raemdonck K . Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across. Adv Drug Deliv Rev. 2021; 176:113900. PMC: 8325057. DOI: 10.1016/j.addr.2021.113900. View

13.

Blakney A, McKay P, Bouton C, Hu K, Samnuan K, Shattock R . Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. Mol Ther. 2020; 29(3):1174-1185. PMC: 7935664. DOI: 10.1016/j.ymthe.2020.11.011. View

14.

Vogel A, Lambert L, Kinnear E, Busse D, Erbar S, Reuter K . Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Mol Ther. 2017; 26(2):446-455. PMC: 5835025. DOI: 10.1016/j.ymthe.2017.11.017. View

15.

Zhong Z, Haltalli M, Holder B, Rice T, Donaldson B, ODriscoll M . The impact of timing of maternal influenza immunization on infant antibody levels at birth. Clin Exp Immunol. 2018; 195(2):139-152. PMC: 6330660. DOI: 10.1111/cei.13234. View

16.

Lutz J, Lazzaro S, Habbeddine M, Schmidt K, Baumhof P, Mui B . Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines. 2017; 2:29. PMC: 5648897. DOI: 10.1038/s41541-017-0032-6. View

17.

Blakney A, McKay P, Hu K, Samnuan K, Jain N, Brown A . Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. J Control Release. 2021; 338:201-210. PMC: 8412240. DOI: 10.1016/j.jconrel.2021.08.029. View

18.

Huysmans H, Zhong Z, De Temmerman J, Mui B, Tam Y, Mc Cafferty S . Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin. Mol Ther Nucleic Acids. 2019; 17:867-878. PMC: 6722285. DOI: 10.1016/j.omtn.2019.08.001. View

19.

Seo S, Kwon H, Song J, Byun Y, Seong B, Kawai T . MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol. 2010; 84(24):12713-22. PMC: 3004294. DOI: 10.1128/JVI.01675-10. View

20.

Erasmus J, Khandhar A, Guderian J, Granger B, Archer J, Archer M . A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. Mol Ther. 2018; 26(10):2507-2522. PMC: 6171036. DOI: 10.1016/j.ymthe.2018.07.010. View